Archives
-
Miltefosine: PI3K/Akt and Myeloid Evidence
2026-08-14
Miltefosine, also called hexadecyl 2-(trimethylazaniumyl)ethyl phosphate, is an experimental PI3K/Akt pathway inhibitor with cell-line, xenograft, antiviral, metabolic, and hematopoietic findings. Recent evidence also links the compound to Ras/MEK/ERK-dependent neutrophil differentiation, but this does not establish one universal mechanism across models.
-
Gap26: Connexin 43 Mimetic Peptide Guide
2026-08-13
Learn how Gap26 (Val-Cys-Tyr-Asp-Lys-Ser-Phe-Pro-Ile-Ser-His-Val-Arg) Connexin 43 Mimetic Peptide, SKU A1044, can help laboratories distinguish connexin 43-mediated signaling from nonspecific effects in viability, proliferation, calcium, and ATP assays. This scenario-based guide covers assay compatibility, preparation, interpretation, and practical product selection.
-
Cyclic di-GMP Workflows for Biofilm and STING Research
2026-08-13
Cyclic di-GMP connects bacterial biofilm persistence studies with STING-focused immune modulation research. This guide translates its antitoxin activity and mammalian STING agonism into practical workflows, assay controls, and troubleshooting strategies.
-
How Near-Death Cells Acquire Metastatic States
2026-08-12
Conod, Silvano, and Ruiz i Altaba show that tumor cells surviving an impending cell-death episode can enter stable prometastatic states called PAMEs. The study connects ER stress, PERK-CHOP signaling, GLI/NANOG-associated reprogramming, and cytokine-mediated recruitment of migratory neighboring cells, providing a mechanistic framework for how metastasis may originate within primary tumors.
-
CPI-613 Workflows for Mitochondrial Cancer Studies
2026-08-12
CPI-613 enables mechanism-led studies of mitochondrial energy failure, apoptosis, and tumor-cell metabolic plasticity. This practical guide connects PDH/KGDH perturbation with assay design, combination testing, and the PDHA1–cuproptosis findings reported in resistant prostate cancer.
-
Quercetin: A Context-Aware PI3K Assay Strategy
2026-08-11
Quercetin is a mechanistically versatile PI3K inhibitor whose effects span inflammatory signaling, mitochondrial apoptosis, and cell cycle regulation. This guide develops an assay-centered framework that connects cancer research with emerging neuroinflammation findings without overstating translational evidence.
-
Rifampin Workflows for Bacterial Transcription Studies
2026-08-11
Rifampin provides a practical, mechanism-based way to interrupt bacterial transcription and connect RNA output with growth, survival, and resistance phenotypes. This guide combines solvent handling, time-course design, synthetic biology use cases, and troubleshooting strategies for reproducible bench workflows.
-
EphA2 Synthetic Lethality in MYC-Driven TNBC
2026-08-10
A 2026 pre-proof study used a chemogenetic screen of approximately 600 kinase inhibitors to identify EphA2 inhibition as a selective vulnerability in MYC-driven triple-negative breast cancer. The lead compound ALW-II-41-27 induced p53-independent intrinsic apoptosis and reduced tumor growth in two TNBC xenograft models, providing a rationale for further genetic, pharmacological, and translational validation.
-
ABT-737 Workflows for BCL-2-Dependent Apoptosis
2026-08-09
ABT-737 provides a practical pharmacological way to test whether cancer cells rely on anti-apoptotic BCL-2 proteins for survival. This workflow combines dose-response design, mitochondrial readouts, and BAX/BAK-aware interpretation for lymphoma, multiple myeloma, small-cell lung cancer, and AML models.
-
Mechanical Stress, Cytoskeleton, and Autophagy
2026-08-08
The reference study shows that compression-induced autophagy depends primarily on cytoskeletal microfilaments, while microtubules make a supporting contribution. By combining cytoskeletal perturbation with fluorescence imaging and western blotting in human cell lines, the work provides direct evidence that the cytoskeleton is an active mechanotransduction component rather than merely a structural scaffold.
-
Ciclesonide Workflows for Airway Research
2026-08-07
Build reproducible airway inflammation assays around Ciclesonide activation, glucocorticoid receptor binding, and lung-cell exposure. The workflow also clarifies how to evaluate ERAD concepts without confusing ciclesonide with the desonide warhead used in ERADECs.
-
Homoharringtonine: Cytotoxic Alkaloid Workflows in Cancer &
2026-08-07
Homoharringtonine stands out as a cytotoxic alkaloid with proven efficacy in both cancer biology and SARS-CoV-2 antiviral research. This article bridges advanced laboratory workflows, protocol optimization, and practical troubleshooting to empower researchers using APExBIO's Homoharringtonine for rapid, mechanistically targeted experimentation.
-
Caffeine as a Precision Modulator in Cancer and Metabolic Re
2026-08-06
Explore how Caffeine (1,3,7-trimethylpurine-2,6-dione) uniquely enables advanced cancer cell line inhibition and metabolic pathway studies. This article delivers a deeper, evidence-driven framework for leveraging Caffeine in translational research.
-
Azithromycin: Protocol Enhancements for Bacterial Infection
2026-08-06
Azithromycin stands out as a macrolide antibiotic uniquely tailored for modern bacterial infection research and trypanosomosis animal models. This article delivers actionable workflow refinements, troubleshooting strategies, and cross-validated protocol insights to maximize its impact in applied bench settings.
-
ATS-9R: Precision Gene Silencing in Adipocytes & Macrophages
2026-08-05
ATS-9R (Adipocyte-targeting sequence-9-arginine) enables highly selective, non-viral gene delivery to white adipose tissue, unlocking new potential for metabolic disease research. Its prohibitin-mediated targeting and robust intracellular release drive efficient gene silencing in adipocytes and adipose tissue macrophages, as demonstrated in cutting-edge studies on obesity, insulin resistance, and gestational diabetes.